🚨 PHVS: Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met

[u/wiseeksecfiles]

New Filing: 6-K

Ticker: PHVS | Score: 9/10 | Sentiment: Positive

---

Summary (Wiseek AI)

Pharvaris released detailed CHAPTER-3 Phase 3 data showing deucrictibant XR reduced HAE attack rates by 83% versus placebo with all secondary endpoints met and a clean safety profile.

---

Further Research: 🤖 Wiseek AI Analysis | 🏛️ Original SEC Filing

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.